SMAD9 and idiopathic pulmonary arterial hypertension: In this program, all iPAH/PVOD patients in our cohort who were not previously genetically tested and those who tested negative on prior analysis for BMPR2 and SMAD9 variants were (re-)contacted for (additional) genetic testing.